Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line docetaxel plus lanreotide in metastatic hormone-refractory prostate carcinoma progressing on first-line docetaxel
2009-017596-26Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Mar 2010
- Modality
- Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and lanreotide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathologic response. Started Mar 2010; status: active.
02
Drugs
docetaxellanreotide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2009-017596-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017596-26.